Reimbursement granted with no restrictions to the label
Alimera to begin selling later in Q3

ATLANTA, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has been granted reimbursement for ILUVIEN^® (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for non-infectious uveitis affecting the posterior segment in Portugal. Reimbursement was granted by the National Authority of Medicines and Health Products (INFARMED) with no change to the current label.